Abstract
To evaluate quality of life and patient preference for schizophrenia treatment in a community based study comparing the use of aripiprazole to the standard of care (SOC). This open-label, 26-week, multi-centre, randomised study compared aripiprazole with SOC (olanzapine, quetiapine or risperidone) in patients with schizophrenia (DSM-IV-TR criteria). The primary effectiveness variable was the mean total score of the Investigator Assessment Questionnaire (IAQ) at Week 26. The outcome research variables included the Preference of Medicine (POM) questionnaire, the Quality of Life Scale (QLS), and the EuroQoL-5D (EQ-5D). The results from these outcome research variables are the focus of this paper addressing quality of life and patient preference. A total of 555 patients were randomised to receive aripiprazole (n=284) or SOC (n=271). The OC data at Week 26, reported that more respondents rated the study medication as 'much better' compared with their previous medication in the aripiprazole group versus SOC for patients (59% vs 35%, P<0.001) and caregivers (58% vs 30%, P=0.014). The improvement in QLS total score was also significantly greater in the aripiprazole group compared with SOC--mean change from baseline in QLS total score o...Continue Reading
References
Jan 1, 1984·Schizophrenia Bulletin·D W HeinrichsW T Carpenter
Nov 21, 1997·Medical Care·P Dolan
Nov 5, 1990·Health Policy·UNKNOWN EuroQol Group
Nov 7, 2000·PharmacoEconomics·E Lindström, K Bingefors
Jul 11, 2002·Psychopharmacology·A Karow, D Naber
Sep 12, 2002·Schizophrenia Research·L VorugantiA Awad
May 21, 2003·Acta Psychiatrica Scandinavica. Supplementum·L PrietoUNKNOWN SOHO Study Group
Jun 11, 2003·Schizophrenia Bulletin·Josephine MauskopfDavid L Grainger
Feb 18, 2004·Current Medicinal Chemistry·C Simon SebastianPeter F Buckley
Apr 2, 2004·The American Journal of Psychiatry·Todd P GilmerDilip V Jeste
Jun 18, 2004·Current Medical Research and Opinion·L PrietoJ C Gómez
Nov 4, 2004·CNS Drugs·A George Awad, Lakshmi N P Voruganti
Jan 27, 2005·Social Psychiatry and Psychiatric Epidemiology·Christiane RoickMatthias C Angermeyer
Feb 11, 2005·Acta Psychiatrica Scandinavica·J M HaroUNKNOWN SOHO advisory board
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Feb 18, 2006·Schizophrenia Research·Rajiv TandonDavid T Crandall
Sep 26, 2006·Medical Hypotheses·Alex J Mitchell
Oct 4, 2006·Archives of General Psychiatry·Peter B JonesShôn W Lewis
Oct 19, 2006·Journal of Psychopharmacology·Henry A Nasrallah, Rob Lasser
Jun 9, 2007·European Psychiatry : the Journal of the Association of European Psychiatrists·Robert KerwinJean-Noël Beuzen
Aug 21, 2007·Current Medical Research and Opinion·Jürgen WolfWolfgang Maier
Citations
Jun 23, 2012·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·M FranzT Meyer
Jun 13, 2013·CNS Drugs·A George Awad, Lakshmi N P Voruganti
Feb 17, 2010·AIDS Patient Care and STDs·Sally L HodderUNKNOWN AI266073 Study Group
Nov 6, 2009·Current Opinion in Psychiatry·Yu-Tao XiangGabor S Ungvari
Jun 27, 2009·Neuropsychiatric Disease and Treatment·Salvatore Gentile
Apr 3, 2010·Neuropsychiatric Disease and Treatment·Izchak KohenSum Lam
Feb 3, 2012·CNS Drugs·Jamie D Croxtall
Feb 13, 2016·Expert Opinion on Pharmacotherapy·Steven G Potkin, Adrian Preda
Jan 5, 2014·The Cochrane Database of Systematic Reviews·Priya KhannaJun Xia
Jul 24, 2012·Early Intervention in Psychiatry·Yu-Shu HuangLiang-Jen Wang